Sunday, September 11, 2022

More transmissible and immune evasive subvariant BA.2.75.2 present in Singapore

 Research, editing : Gan Yung Chyan, KUCINTA SETIA

News on disease control

News (1)

More transmissible and evasive Omicron variant BA.2.75.2 now present in Singapore

Image : Web Screenshot

According to consolidated Indian and Thai media, India's genome sequence agency INSACOG, has warned on 11 September 2022 that Omicron covi variant BA.2.75 has mutated to become BA.2.75.2 and may become more transmissible and immune evasive.

BA.2.75 has spawned what has been designated "BA.2.75.2", which recently drew the attention of  experts tracking mutations in SARS-CoV-2 (covi). Cao Yunlong, an immunologist of Peking University, tweeted, " BA.2.75.2 is currently the most immune evasive strain we have tested so far".

Maharashtra's coordinator for covi genome sequencing, Dr Rajesh Karyakarte, confirmed that BA.2.75 is "mutating further" .

"It is vying for dominance by packing in more immune evasive mutations", Karyakarte said.

The BA.2.75.2 subvariant is defined by mutations S:R346T, S;F486S, S:D119N and was first detected in India. Its earliest sequences are from India, Chile, England (UK), Singapore, Spain and Germany but it is now in over eight countries including Singapore and India.

According to INSACOG, experts globally are tracking BA.2.75.2 because BA.2.75 went on to replace BA.4 and BA.5. This makes BA.2.75.2 more infectious than BA.2.75.

News (2)

Evusheld and Bebtolevimab do not have effect on BA.2.75.2

According to Cao Yunlong, the plasma from all various Omicron variants breakthrough infections including teh BA.5 have no effect against the Omicron covi sub-lineage BA.2.75.2.

The study team at Peking University said that Evusheld and Bebtolevimab have no efficacy against BA.2.75.2.

The drug Evusheld, a combination of two human monoclonal antibodies Tixagevimab and Cilgavimab, is ineffective agianst BA.2.75.2 because of 486S and 346T mutations found on BA.2.75.2, and the fold change on NT50 of the BA.2.75.2 is nearly three-fold compared to BA.5, contributed from both RBD and NTD mutations.

Bebtolevimab has no efficacy against BA.2.75.2 but it can neutralize BA.5.9, BA.4.6 and BA.4.7.

News (3)

The ten countries where BA.2.75.2 is appearing

The Chinese and Indian scientists said BA.2.75.2 is rising exponentially in certain parts of India including Maharashtra, Pune as well as in Singapore, Spain, Japan, Germany, South Korea, Chile, Australia, the UK and U.S.



Video

Interpretation of a rare phenomenon on the Mid-Autumn Festival: the CCP's civil war is bloodshed❗❗



No comments:

Post a Comment

StayGate Pictures : KLIA Transit and KLIA Terminal 2

  Pictures copyright by : Gan Yung Chyan, KUCINTA SETIA